Artificial Intelligence Model can Predict Disease Progression During Aging

New computer model developed can help assess long-term chronic drug therapies and help clinicians develop more effective treatments for complex diseases.

New model using artificial intelligence (AI) has been developed by a team of University at Buffalo researchers to know the progression of chronic diseases during old age.

Published in Oct. in the Journal of Pharmacokinetics and Pharmacodynamics, the model assesses metabolic and cardiovascular biomarkers – measurable biological processes such as cholesterol levels, body mass index, glucose and blood pressure – to calculate health status and disease risks across a patient’s lifespan.

Penicillin Cuts Rheumatic Heart Disease Progression
In children and adolescents, treatment with penicillin antibiotic significantly decreased the risk of underlying rheumatic heart disease progression, stated a new study.

‘New computer model developed can help assess long-term chronic drug therapies and help clinicians develop more effective treatments for complex diseases.’

The findings are critical due to the increased risk of developing metabolic and cardiovascular diseases with aging, a process that has adverse effects on cellular, psychological and behavioral processes.

“There is an unmet need for scalable approaches that can provide guidance for pharmaceutical care across the lifespan in the presence of aging and chronic co-morbidities,” says lead author Murali Ramanathan, PhD, professor of pharmaceutical sciences in the UB School of Pharmacy and Pharmaceutical Sciences. “This knowledge gap may be potentially bridged by innovative disease progression modeling.”

The model could facilitate the assessment of long-term chronic drug therapies, and help clinicians monitor treatment responses for conditions such as diabetes, high cholesterol and high blood pressure, which become more frequent with age, says Ramanathan.

New Study Rules Out an Antioxidant Therapy for Slowing Parkinson's Disease Progression
The hypothesis that raising the brain levels of the natural antioxidant urate could slow the progression of Parkinson’s disease (PD) has been disproven by researchers.

Additional investigators include first author and UB School of Pharmacy and Pharmaceutical Sciences alumnus Mason McComb, PhD; Rachael Hageman Blair, PhD, associate professor of biostatistics in the UB School of Public Health and Health Professions; and Martin Lysy, PhD, associate professor of statistics and actuarial science at the University of Waterloo.

The research examined data from three case studies within the third National Health and Nutrition Examination Survey (NHANES) that assessed the metabolic and cardiovascular biomarkers of nearly 40,000 people in the United States.

Parkinson's Disease Progression Slowed Down by Experimental Drugs in Mice Study
An experimental drug which has the similar compounds to treat diabetes was found to slow the progression of Parkinson's disease when administered in mice

Biomarkers, which also include measurements such as temperature, body weight and height, are used to diagnose, treat and monitor overall health and numerous diseases.

The researchers examined seven metabolic biomarkers: body mass index, waist-to-hip ratio, total cholesterol, high-density lipoprotein cholesterol, triglycerides, glucose and glycohemoglobin. The cardiovascular biomarkers examined include systolic and diastolic blood pressure, pulse rate and homocysteine.

Obesity Accelerates Kidney Disease Progression
Mouse study finds obesity-related energy imbalance in kidneys. Obesity, metabolic syndrome accelerate the development of kidney disease.

By analyzing changes in metabolic and cardiovascular biomarkers, the model “learns” how aging affects these measurements. With machine learning, the system uses a memory of previous biomarker levels to predict future measurements, which ultimately reveal how metabolic and cardiovascular diseases progress over time.

Source-Eurekalert